Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Recalls, complaints & regulation
Arrowhead Pharmaceuticals (ARWR): recalls and clinical trials
Arrowhead Pharmaceuticals (ARWR) beyond its filings: 1 recall in the last 12 months (1 in five years, 0 Class I); 12 active clinical trials.
Latest recalls
- 2026-08-26 · FDA device · Arrow-LOK Implant, REF: 21-253519, 21-253522, 21-253525, 21-253528, 21-253530, 21-253533, 21-253535, 21-253540, 21-253545, 21-253550, 21-353513, 21-
Arrowhead Pharmaceuticals' latest quarter
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.
Questions
Has Arrowhead Pharmaceuticals had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 1 in the last 12 months.
How many clinical trials does Arrowhead Pharmaceuticals have?
12 active studies on ClinicalTrials.gov, 4 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.